Description

Lenvanix (Lenvatinib) is a medication used to treat several types of cancer:

• Differentiated thyroid cancer (DTC): The recommended dosage is 24 mg orally once daily.
• Renal cell carcinoma (RCC): The recommended dosage is 18 mg orally once daily in combination with everolimus 5 mg orally once daily.
• Hepatocellular carcinoma (HCC): The recommended dosage is based on actual body weight – 12 mg orally once daily for patients ≥60 kg, or 8 mg orally once daily for patients <60 kg.

Lenvatinib is a multi-kinase inhibitor that interrupts the pathways of VEGFR1, VEGFR2, and VEGFR3, which are involved in tumor growth and angiogenesis. Common side effects include hypertension, fatigue, diarrhea, decreased appetite, and palmar-plantar erythrodysesthesia syndrome.The Lenvanix 4 mg capsules are one of the available strengths for this medication, sold in 30-count bottles.

Mechanism of Action

• Lenvatinib is a multi-kinase inhibitor that interrupts the pathways of VEGFR1, VEGFR2, and VEGFR3, which are involved in tumor growth and angiogenesis.

Indications and Dosing

• Differentiated Thyroid Cancer (DTC): Recommended dose is 24 mg orally once daily.
• Renal Cell Carcinoma (RCC): Recommended dose is 18 mg orally once daily in combination with everolimus 5 mg orally once daily.
• Hepatocellular Carcinoma (HCC): Recommended dose is 12 mg orally once daily for patients ≥60 kg, or 8 mg orally once daily for patients <60 kg.

Product Details

• Lenvanix 4 mg capsules are one of the available strengths for this medication, sold in 30-count bottles.

Common Side Effects

• Hypertension, fatigue, diarrhea, decreased appetite, and palmar-plantar erythrodysesthesia syndrome.

Key Benefits

• Treats differentiated thyroid cancer (DTC), renal cell carcinoma (RCC), and hepatocellular carcinoma (HCC).
• Interrupts the pathways of VEGFR1, VEGFR2, and VEGFR3, which are involved in tumor growth and angiogenesis.

Key Ingredients

• The active ingredient is lenvatinib, a multi-kinase inhibitor.
• Lenvatinib binds to the adenosine 5′-triphosphate binding site of VEGFR2 and inhibits tyrosine kinase activity and associated signaling pathways.
• It also inhibits the kinase activities of other receptor tyrosine kinases implicated in pathogenic angiogenesis, tumor growth, and cancer progression, including FGFR1-4, PDGFRα, KIT, and RET.

The recommended dosages are:

• DTC: 24 mg orally once daily
• RCC: 18 mg orally once daily with everolimus 5 mg orally once daily
• HCC: 12 mg orally once daily for patients ≥60 kg, or 8 mg orally once daily for patients <60 kg

Mechanism of Action of Lenvanix (Lenvatinib) 4mg Capsules

The key mechanisms of action of lenvatinib, the active ingredient in Lenvanix, are:Inhibition of Vascular Endothelial Growth Factor (VEGF) Receptors

• Lenvatinib inhibits the kinase activities of VEGF receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4) .
• VEGF signaling plays a crucial role in pathogenic angiogenesis, tumor growth, and cancer progression.

Inhibition of Other Receptor Tyrosine Kinases

• In addition to VEGF receptors, lenvatinib inhibits the kinase activities of other receptor tyrosine kinases implicated in cancer, including:
  • Fibroblast growth factor receptors FGFR1, 2, 3, and 4 
  • Platelet-derived growth factor receptor alpha (PDGFRα) 
  • KIT and RET proto-oncogenes 
• Inhibition of these additional targets disrupts multiple signaling pathways involved in tumor growth and cancer progression.
  

  Lenvatinib

  Anti-cancer medication

  More

  Brand name

  Lenvima

  Developer

  Eisai Co.

  Primary use

  Treatment of certain kinds of thyroid cancer, renal cell carcinoma, hepatocellular carcinoma

  Chemical Structure of Lenvanix (Lenvatinib) 4mg Capsules

  The chemical structure of lenvatinib, the active ingredient in Lenvanix 4mg capsules, is:\ce{C21H19ClN4O4}The IUPAC name is:4-{3-chloro-4-[(cyclopropylcarbamoyl)amino]phenoxy}-7-methoxyquinoline-6-carboxamideThe key structural features are:

  • A quinoline core with a 7-methoxy group and a 6-carboxamide group
  • A 3-chloro-4-[(cyclopropylcarbamoyl)amino]phenoxy substituent attached at the 4-position of the quinoline
  • A cyclopropane ring in the carbamoyl substituent

  The molecular weight of lenvatinib is 426.86 g/mol.This multi-kinase inhibitor structure allows lenvatinib to target a variety of receptor tyrosine kinases involved in tumor growth and angiogenesis, including VEGFR1-3, FGFR1-4, PDGFRα, KIT, and RET.

  Dosage

  The recommended dosages of Lenvanix (lenvatinib) are:Differentiated Thyroid Cancer (DTC):

  • 24 mg orally once daily

  Renal Cell Carcinoma (RCC):

  • 18 mg orally once daily in combination with everolimus 5 mg orally once daily

  Hepatocellular Carcinoma (HCC):

  • 12 mg orally once daily for patients ≥60 kg
  • 8 mg orally once daily for patients <60 kg

  The dosage may need to be modified for patients with renal or hepatic impairment.

  Storage

  Lenvanix 4 mg capsules should be stored at room temperature, below 30°C (86°F).

  Reviews

  There are no user reviews available for Lenvanix (Lenvatinib) 4 mg capsules. As an oncology medication, it is typically prescribed and monitored by healthcare professionals rather than being available for direct consumer purchase and review.The clinical trial data and prescribing information indicate that Lenvanix has demonstrated efficacy in treating differentiated thyroid cancer, renal cell carcinoma, and hepatocellular carcinoma. However, the medication does carry significant side effect risks that require close medical supervision, such as hypertension, fatigue, diarrhea, and liver/kidney dysfunction.Patients should consult their oncologist to determine if Lenvanix is an appropriate treatment option based on their specific cancer type and health status. The dosage and administration must be carefully managed by the prescribing physician.